8-KMaterial AgreementsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Material Agreement (Jan 31, 2023)

Filed January 31, 2023For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on January 31, 2023, announcing an amendment to its Share Purchase Agreement with Amgen Inc. This amendment, effective January 30, 2023, involves Amgen relinquishing its right to appoint a director to BeOne's board of directors. This change reflects BeOne's global growth and is not expected to impact the company's strategic direction or operations. While Amgen is no longer appointing a director, the current designee, Anthony C. Hooper, who was Amgen's appointed director, will continue to serve on BeOne's board. Mr. Hooper was re-elected by shareholders in 2022 for a term ending in 2025, indicating continued confidence from the broader shareholder base. This development is primarily a governance adjustment resulting from the evolution of the relationship between the two companies.

Key Highlights

  • 1Amgen has relinquished its right to appoint a director to BeOne Medicines' board of directors.
  • 2The change is effective as of January 30, 2023, via Amendment No. 3 to the Share Purchase Agreement.
  • 3BeOne Medicines cites its global growth as the reason for Amgen's decision.
  • 4The current director designee, Anthony C. Hooper, will remain on the board.
  • 5Mr. Hooper's current term as a director ends in 2025, having been re-elected by shareholders in 2022.
  • 6The original Share Purchase Agreement involved Amgen investing approximately $2.78 billion for ordinary shares (ADSs) in BeOne Medicines.

Frequently Asked Questions

The main event is the amendment to the Share Purchase Agreement between BeOne Medicines Ltd. and Amgen Inc., where Amgen has elected to give up its right to appoint a director to BeOne's board.

According to the filing, the decision is on account of BeOne's global growth, suggesting it's a governance adjustment rather than an operational or strategic shift. The company does not indicate any negative impact on its operations or strategy.

Anthony C. Hooper was Amgen's designated director on BeOne Medicines' board. Following Amgen's relinquishment of its appointment right, Mr. Hooper will continue to serve as a director, as he was re-elected by shareholders in 2022 for a term ending in 2025.

The filing focuses solely on the director appointment right. It does not mention any changes to Amgen's equity stake or the original investment made under the Share Purchase Agreement, which was approximately $2.78 billion.